Neutrophil Immunomodulatory Activity of Farnesene, a Component of Artemisia dracunculus Essential Oils

dc.contributor.authorSchepetkin, Igor A.
dc.contributor.authorÖzek, Gulmira
dc.contributor.authorÖzek, Temel
dc.contributor.authorKirpotina, Liliya N.
dc.contributor.authorKhlebnikov, Andrei I.
dc.contributor.authorKlein, Robyn A.
dc.contributor.authorQuinn, Mark T.
dc.date.accessioned2022-10-20T15:35:11Z
dc.date.available2022-10-20T15:35:11Z
dc.date.issued2022-05
dc.description.abstractDespite their reported therapeutic properties, not much is known about the immunomodulatory activity of essential oils present in Artemisia species. We isolated essential oils from the flowers and leaves of five Artemisia species: A. tridentata, A. ludoviciana, A. dracunculus, A. frigida, and A. cana. The chemical composition of the Artemisia essential oil samples had similarities and differences as compared to those previously reported in the literature. The main components of essential oils obtained from A. tridentata, A. ludoviciana, A. frigida, and A. cana were camphor (23.0–51.3%), 1,8-cineole (5.7–30.0%), camphene (1.6–7.7%), borneol (2.3–14.6%), artemisiole (1.2–7.5%), terpinen-4-ol (2.0–6.9%), α-pinene (0.8–3.9%), and santolinatriene (0.7–3.5%). Essential oils from A. dracunculus were enriched in methyl chavicol (38.8–42.9%), methyl eugenol (26.1–26.4%), terpinolene (5.5–8.8%), (E/Z)-β-ocimene (7.3–16.0%), β-phellandrene (1.3–2.2%), p-cymen-8-ol (0.9–2.3%), and xanthoxylin (1.2–2.2%). A comparison across species also demonstrated that some compounds were present in only one Artemisia species. Although Artemisia essential oils were weak activators of human neutrophils, they were relatively more potent in inhibiting subsequent neutrophil Ca2+ mobilization with N-formyl peptide receptor 1 (FPR1) agonist fMLF- and FPR2 agonist WKYMVM, with the most potent being essential oils from A. dracunculus. Further analysis of unique compounds found in A. dracunculus showed that farnesene, a compound with a similar hydrocarbon structure as lipoxin A4, inhibited Ca2+ influx induced in human neutrophils by fMLF (IC50 = 1.2 μM), WKYMVM (IC50 = 1.4 μM), or interleukin 8 (IC50 = 2.6 μM). Pretreatment with A. dracunculus essential oils and farnesene also inhibited human neutrophil chemotaxis induced by fMLF, suggesting these treatments down-regulated human neutrophil responses to inflammatory chemoattractants. Thus, our studies have identified farnesene as a potential anti-inflammatory modulator of human neutrophils.en_US
dc.identifier.citationSchepetkin, I.A.; Özek, G.; Özek, T.; Kirpotina, L.N.; Khlebnikov, A.I.; Klein, R.A.; Quinn, M.T. Neutrophil Immunomodulatory Activity of Farnesene, a Component of Artemisia dracunculus Essential Oils. Pharmaceuticals 2022, 15, 642. https://doi.org/10.3390/ ph15050642en_US
dc.identifier.issn1424-8247
dc.identifier.urihttps://scholarworks.montana.edu/handle/1/17291
dc.language.isoen_USen_US
dc.publisherMDPI AGen_US
dc.rightscc-byen_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en_US
dc.subjectanti-imflammatoryen_US
dc.subjectartemisiaen_US
dc.subjectcalcium fluxen_US
dc.subjectchemotaxisen_US
dc.subjectessential oilsen_US
dc.subjectfarneseneen_US
dc.subjectmonoterpeneen_US
dc.subjectneutrophilen_US
dc.titleNeutrophil Immunomodulatory Activity of Farnesene, a Component of Artemisia dracunculus Essential Oilsen_US
dc.typeArticleen_US
mus.citation.extentfirstpage1en_US
mus.citation.extentlastpage17en_US
mus.citation.issue5en_US
mus.citation.journaltitlePharmaceuticalsen_US
mus.citation.volume15en_US
mus.identifier.doi10.3390/ph15050642en_US
mus.relation.collegeCollege of Agricultureen_US
mus.relation.departmentMicrobiology & Cell Biology.en_US
mus.relation.universityMontana State University - Bozemanen_US

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
schepetkin-artemisia-2022.pdf
Size:
1.86 MB
Format:
Adobe Portable Document Format
Description:
artemisia essential oils

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
826 B
Format:
Item-specific license agreed upon to submission
Description:
Copyright (c) 2002-2022, LYRASIS. All rights reserved.